Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials

July 2016 in “ The Journal of Sexual Medicine ”

Luhao Liu, Shankun Zhao, Futian Li, Ermao Li, Ran Kang, Lianmin Luo, Jin-Yan Luo, Shouhong Wan, Zhigang Zhao

5α-reductase inhibitors 5ARIs sexual dysfunction erectile dysfunction decreased libido benign prostatic hyperplasia BPH androgenetic alopecia AGA dutasteride finasteride 5-alpha reductase inhibitors low libido male pattern baldness Propecia Avodart

From the encyclopedia

Dutasteride →

Heavy duty finasteride that comes with higher risks

Finasteride →

Frontline, gold standard treatment for combatting androgenic alopecia

Studysummary This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on sciencedirect.com →

Discuss this study in the Community →

Research cited in this study

27 / 27 results

research Persistent Sexual Dysfunction and Suicidal Ideation in Young Men Treated with Low-Dose Finasteride: A Pharmacovigilance Study

69 citations , July 2015 in “Pharmacotherapy”

This study found that low-dose finasteride use in young men was associated with higher reporting of persistent sexual dysfunction, with some cases linked to suicidal ideation.

research Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-Analysis

44 citations , April 2015 in “PubMed”

This study reports that clinical trials of finasteride for androgenic alopecia provide insufficient and systematically biased safety data, with most participants unrepresentative of those in pivotal trials that led to FDA approval.

research 5α-Reductase Inhibitors Increase Acute Coronary Syndrome Risk in Patients with Benign Prostate Hyperplasia

6 citations , March 2015 in “Journal of Endocrinological Investigation”

This study suggests that using both finasteride and dutasteride may increase the risk of acute coronary syndrome in patients with benign prostate hyperplasia.

research 5α-Reductase Type 1 Deficiency or Inhibition Predisposes to Insulin Resistance, Hepatic Steatosis, and Liver Fibrosis in Rodents

93 citations , September 2014 in “Diabetes”

This study found that male 5αR1 knockout mice and obese Zucker rats treated with finasteride showed increased insulin resistance and hepatic steatosis, potentially implicating 5α-reductase activity in metabolic liver disease development.

research Androgen Levels and Semen Parameters Among Former Users of Finasteride With Persistent Sexual Adverse Effects

15 citations , September 2014 in “JAMA Dermatology”

This discussion highlights the use of minimal incision extraction for lipoma removal, noting that it is a favored technique among dermatologists due to its efficiency, despite some hesitance with larger lipomas.

A Population-Based Nested Case-Control Study: The Use of 5-Alpha-Reductase Inhibitors and the Increased Risk of Osteoporosis Diagnosis in Patients with Benign Prostate Hyperplasia

research A Population-Based Nested Case-Control Study: The Use of 5-Alpha-Reductase Inhibitors and the Increased Risk of Osteoporosis Diagnosis in Patients with Benign Prostate Hyperplasia

22 citations , August 2014 in “Clinical endocrinology”

This study suggests that the use of finasteride for benign prostate hyperplasia may increase the risk of osteoporosis diagnosis, particularly at higher doses.

A Randomized, Active- and Placebo-Controlled Study of the Efficacy and Safety of Different Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects with Androgenetic Alopecia

research A Randomized, Active- and Placebo-Controlled Study of the Efficacy and Safety of Different Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects with Androgenetic Alopecia

97 citations , January 2014 in “Journal of The American Academy of Dermatology”

This study found that dutasteride increased hair growth and restoration in men with androgenetic alopecia more effectively than finasteride and was well tolerated over 24 weeks.

The Efficacy and Safety of 5α-Reductase Inhibitors in Androgenetic Alopecia: A Network Meta-Analysis and Benefit–Risk Assessment of Finasteride and Dutasteride

research The Efficacy and Safety of 5α-Reductase Inhibitors in Androgenetic Alopecia: A Network Meta-Analysis and Benefit–Risk Assessment of Finasteride and Dutasteride

66 citations , June 2013 in “Journal of Dermatological Treatment”

This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.

research 5α-Reductases in Human Physiology: An Unfolding Story

44 citations , July 2012 in “Endocrine Practice”

This review highlights the need for a deeper understanding of 5alpha-reductases and neuroactive steroids to reduce potential adverse effects of 5alpha-reductase inhibitors used for conditions like benign prostatic hyperplasia and androgenic alopecia, but reports no new clinical results.

research British Association of Dermatologists’ Guidelines for the Management of Alopecia Areata 2012

218 citations , April 2012 in “British Journal of Dermatology”

This updated guideline from the British Association of Dermatologists discusses current recommendations for managing alopecia areata but reports no new clinical research findings.

research Guidelines for the Management of Androgenetic Alopecia (2010)

38 citations , December 2011 in “Journal of Dermatology”

This article reviews current guidelines for managing androgenetic alopecia and highlights the need for guidelines tailored to Japan; it reports no new clinical results.

research Efficacy and Safety of Finasteride Therapy for Androgenetic Alopecia

152 citations , October 2010 in “Archives of Dermatology”

This study found that daily oral finasteride may increase hair count and improve hair appearance assessments in men with androgenetic alopecia, but it also appears to raise the risk of sexual dysfunction.

Efficacy, Safety, and Tolerability of Dutasteride 0.5 mg Once Daily in Male Patients with Male Pattern Hair Loss: A Randomized, Double-Blind, Placebo-Controlled, Phase III Study

research Efficacy, Safety, and Tolerability of Dutasteride 0.5 mg Once Daily in Male Patients with Male Pattern Hair Loss: A Randomized, Double-Blind, Placebo-Controlled, Phase III Study

92 citations , June 2010 in “Journal of The American Academy of Dermatology”

This study found that 0.5 mg of dutasteride significantly improved hair growth compared to placebo and was well tolerated over six months in men with male pattern hair loss.

research Androgenetic Alopecia: Clinical Features, Classification, and Treatments

103 citations , June 2007 in “Endocrinology and Metabolism Clinics of North America”

This article discusses treatment options for androgenetic alopecia, noting that medical interventions like finasteride and minoxidil can halt and partially reverse hair loss in mild to moderate cases, especially when combined with surgery.

The Importance of Dual 5α-Reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-Controlled Study of Dutasteride Versus Finasteride

research The Importance of Dual 5α-Reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-Controlled Study of Dutasteride Versus Finasteride

215 citations , November 2006 in “Journal of The American Academy of Dermatology”

This study found that dutasteride increased scalp hair growth in men with male pattern hair loss, particularly at a 2.5 mg dose, and was more effective than finasteride over 24 weeks.

research A New Look at the 5-Alpha-Reductase Inhibitor Finasteride

137 citations , March 2006 in “Cns Drug Reviews”

This review explores finasteride's effects on neuroactive steroid levels and their potential influence on disorders like depression and alcohol withdrawal but reports no new clinical findings.

Evaluation of Sexual Function With an International Index of Erectile Function in Subjects Taking Finasteride for Androgenetic Alopecia

research Evaluation of Sexual Function With an International Index of Erectile Function in Subjects Taking Finasteride for Androgenetic Alopecia

44 citations , July 2004 in “Archives of Dermatology”

In this study, treatment with 1 mg of finasteride was associated with stable sexual function, suggesting that sexual side effects may be less common than indicated in clinical trials.

research Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor

408 citations , May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism”

This study found that dutasteride more effectively reduced serum dihydrotestosterone levels than finasteride in patients with benign prostatic hyperplasia.

research The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia

1707 citations , December 2003 in “The New England Journal of Medicine”

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

research Finasteride Increases Anagen Hair in Men with Androgenetic Alopecia

129 citations , October 2000 in “British Journal of Dermatology”

This study found that finasteride increases anagen hair growth in men with androgenetic alopecia.

research Immunohistochemical Localization of Types 1 and 2 5α-Reductase in Human Scalp

100 citations , September 1999 in “British Journal of Dermatology”

This study suggests that finasteride's effect on promoting hair growth in men with androgenetic alopecia may be due to its inhibition of 5aR2 localized in hair follicles.

research Finasteride in the Treatment of Men with Frontal Male Pattern Hair Loss

187 citations , June 1999 in “Journal of The American Academy of Dermatology”

This study reported that finasteride 1 mg/day significantly increased hair growth and slowed hair loss in men with frontal scalp hair thinning over one year, and these benefits continued or improved in the second year.

A Model for the Turnover of Dihydrotestosterone in the Presence of the Irreversible 5α-Reductase Inhibitors GI198745 and Finasteride

research A Model for the Turnover of Dihydrotestosterone in the Presence of the Irreversible 5α-Reductase Inhibitors GI198745 and Finasteride

60 citations , December 1998 in “Clinical Pharmacology & Therapeutics”

Both drugs lower DHT levels, with GI198745 being more effective.

research Finasteride in the Treatment of Men with Androgenetic Alopecia

581 citations , October 1998 in “Journal of The American Academy of Dermatology”

In male pattern hair loss, this study found that finasteride 1 mg daily significantly slowed hair loss and increased hair growth over two years compared to placebo.

The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia

research The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia

1054 citations , February 1998 in “The New England Journal of Medicine”

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.

research Finasteride

187 citations , January 1994 in “The New England Journal of Medicine”

Finasteride treats enlarged prostate and may help with baldness, but effects on sexual function and male fetuses are unclear.

research The Effect of Finasteride in Men with Benign Prostatic Hyperplasia

1040 citations , October 1992 in “The New England Journal of Medicine”

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.